These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 31830936)

  • 1. A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study.
    Yaguchi A; Akahane K; Tsuchioka K; Yonekubo S; Yamamoto S; Tamai Y; Tatemichi S; Takeda H
    BMC Nephrol; 2019 Dec; 20(1):465. PubMed ID: 31830936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Phosphate Binding Capacities of PA21, A Novel Phosphate Binder, with those of other Phosphate Binders in vitro and in vivo.
    Yaguchi A; Yonekubo S; Maruyama I; Tatemichi S; Maruyama K; Kobayashi M
    Drug Res (Stuttg); 2016 May; 66(5):262-9. PubMed ID: 26761712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of pH and phosphate concentration on the phosphate binding capacity of five contemporary binders. An in vitro study.
    Schumacher SP; Schurgers LJ; Vervloet MG; Neradova A
    Nephrology (Carlton); 2019 Feb; 24(2):221-226. PubMed ID: 29479762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure.
    Phan O; Maillard M; Malluche HH; Stehle JC; Funk F; Burnier M
    Biomed Res Int; 2015; 2015():515606. PubMed ID: 26221597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphate Binders Derived from Natural Ores Contain Many Kinds of Metallic Elements Besides Their Active Ingredient Metals.
    Nagano N; Minegishi A; Ito K; Ando T; Tsutsui T; Ogawa T
    Ther Apher Dial; 2018 Dec; 22(6):630-634. PubMed ID: 29989312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure.
    Yaguchi A; Tatemichi S; Takeda H; Kobayashi M
    PLoS One; 2017; 12(7):e0180430. PubMed ID: 28704404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of the phosphate binder, ferric citrate hydrate (JTT-751), about phosphorus absorption-reducing effect in normal rats.
    Matsuo A; Iida A; Tanimoto M; Matsushita M; Miyamoto K
    Ren Fail; 2014 Sep; 36(8):1291-7. PubMed ID: 24975675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.
    Floege J; Covic AC; Ketteler M; Mann J; Rastogi A; Spinowitz B; Rakov V; Lisk LJ; Sprague SM
    Nephrol Dial Transplant; 2017 Nov; 32(11):1918-1926. PubMed ID: 28339993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
    Floege J; Covic AC; Ketteler M; Mann JF; Rastogi A; Spinowitz B; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
    Nephrol Dial Transplant; 2015 Jun; 30(6):1037-46. PubMed ID: 25691681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide.
    Cernaro V; Santoro D; Lacquaniti A; Costantino G; Visconti L; Buemi A; Buemi M
    Int J Nephrol Renovasc Dis; 2016; 9():11-9. PubMed ID: 26893577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients.
    Minakuchi H; Yoshida T; Kaburagi N; Fujino T; Endo S; Takemitsu TY; Yamashita N; Itoh H; Oya M
    Ren Fail; 2020 Nov; 42(1):799-806. PubMed ID: 32779954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide.
    Cozzolino M; Funk F; Rakov V; Phan O; Teitelbaum I
    Curr Drug Metab; 2014; 15(10):953-65. PubMed ID: 25658128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland.
    Gutzwiller FS; Pfeil AM; Ademi Z; Blank PR; Braunhofer PG; Szucs TD; Schwenkglenks M
    Pharmacoeconomics; 2015 Dec; 33(12):1311-24. PubMed ID: 26334991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.
    Coyne DW; Sprague SM; Vervloet M; Ramos R; Kalantar-Zadeh K
    J Nephrol; 2022 Apr; 35(3):875-888. PubMed ID: 35138627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
    Sekercioglu N; Angeliki Veroniki A; Thabane L; Busse JW; Akhtar-Danesh N; Iorio A; Cruz Lopes L; Guyatt GH
    PLoS One; 2017; 12(3):e0171028. PubMed ID: 28248961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study.
    Koiwa F; Yokoyama K; Fukagawa M; Terao A; Akizawa T
    Nephrology (Carlton); 2017 Apr; 22(4):293-300. PubMed ID: 27496336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphate binders in chronic kidney disease: a systematic review of recent data.
    Floege J
    J Nephrol; 2016 Jun; 29(3):329-340. PubMed ID: 26800972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis.
    Bousher A; Al-Makki A; Sutton J; Shepler B
    Clin Ther; 2014 Dec; 36(12):2082-2093. PubMed ID: 25450474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
    St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
    Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphate binders in chronic kidney disease: an updated narrative review of recent data.
    Floege J
    J Nephrol; 2020 Jun; 33(3):497-508. PubMed ID: 31865608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.